Preventing CMV in kidney transplant patients with specific therapies
Kidney transplant Preemptive therapy or Prophylaxis (KPoP) for CMVPreventionin D+R- Recipients
This study is looking at how to better protect kidney transplant patients who haven't had cytomegalovirus (CMV) before, but are getting a kidney from someone who has, by comparing two ways of preventing CMV: taking medicine for a while or waiting to see if they get sick before treating them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11137566 on NIH RePORTER |
What this research studies
This research focuses on improving the prevention of cytomegalovirus (CMV) in kidney transplant recipients who are seronegative for CMV and receive an organ from a seropositive donor. The study compares two approaches: antiviral prophylaxis, which involves taking antiviral medication for a set period, and preemptive therapy, where patients are monitored for CMV and treated only if necessary. The goal is to enhance the immune response against CMV while reducing the duration of antiviral medication. By understanding the effectiveness of these strategies, the research aims to improve patient outcomes and reduce complications related to CMV.
Who could benefit from this research
Good fit: Ideal candidates for this research are kidney transplant recipients who are CMV seronegative and have received an organ from a CMV seropositive donor.
Not a fit: Patients who are not undergoing kidney transplantation or those who are CMV seropositive may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of CMV-related complications in kidney transplant recipients, leading to better overall health and graft survival.
How similar studies have performed: Previous research in liver transplant patients has shown that preemptive therapy can be effective, but this approach has not been extensively tested in kidney transplant recipients.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Limaye, Abhijit Prakash — University of California, San Francisco
- Study coordinator: Limaye, Abhijit Prakash
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.